Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.

被引：0
|
作者：
Liu, Yue
Ding, Kefeng
Xiao, Qian
He, Jinjie
Hu, Hanguang
Du, Jinlin
Zhu, Yuping
Chen, Jiaqi
Liu, Zhuo
Wang, Jianping
Sun, Lifeng
Xu, Dong
Li, Jun
Liao, Xiujun
Wang, Jianwei
Cai, Yibo
Cai, Cheng
Jin, Zhekang
Yuan, Ying
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Colorectal Surg, Jinhua Hosp, Jinhua, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Colorectal Surg, Hangzhou, Zhejiang, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 2, Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-237-255; 281-206-4957-3975-3408-6824; 261-492-12161; 261-492-2769; 613-135-244-3829; 281-318-430; 5; 4; 2; 2414; 1589; 92; 239; 6; 3; 1; 38116-38094-8; 38092-34311; 38092-29234; 38092-18849;
D O I：
10.1200/JCO.2024.42.3_suppl.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
  • [32] Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
    Kienle, Dirk L.
    Dietrich, Daniel
    Ribi, Karin
    Wicki, Andreas
    Quagliata, Luca
    Winterhalder, Ralph C.
    Koeberle, Dieter
    Horber, Daniel
    Bastian, Sara
    Kueng, Marc
    Saletti, Piercarlo
    Helbling, Daniel
    Baertschi, Daniela
    Lugli, Alessandro
    Bernhard, Juerg
    Andrieu, Christiane
    von Moos, Roger
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (02) : 304 - 310
  • [33] Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
    Kienle, D.
    Winterhalder, R.
    Koeberle, D.
    Horber, D.
    Kueng, M.
    Saletti, P.
    Helbling, D.
    Bastian, S.
    Dietrich, D.
    Baertschi, D.
    Pilop, C.
    Von Moos, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S194 - S195
  • [34] Intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer: An update of survival/toxicity and preliminary results of genomic alterations from IMPROVE study
    De Stefano, A.
    Giuliani, F.
    Nasti, G.
    Montesarchio, V.
    Santabarbara, G.
    Leo, S.
    Malapelle, U.
    Rosati, G.
    Lolli, I.
    Tamburini, E.
    Colombo, A.
    Santini, D.
    Silvestro, L.
    Leone, A.
    Vitagliano, C.
    Troncone, G.
    Sobrero, A.
    Giannarelli, D.
    Budillon, A.
    Avallone, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S172 - S173
  • [35] Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease
    Rivera, F.
    Peeters, M.
    Douillard, J-Y.
    Taieb, J.
    Koukakis, R.
    Demonty, G.
    Siena, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer
    Wong, W. W. L.
    Zargar, M.
    Berry, S. R.
    Ko, Y. J.
    Riesco-Martinez, M.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2019, 26 (05) : E597 - E609
  • [37] The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis
    Ciliberto, Domenico
    Staropoli, Nicoletta
    Caglioti, Francesca
    Chiellino, Silvia
    Ierardi, Antonella
    Ingargiola, Rossana
    Botta, Cirino
    Arbitrio, Mariamena
    Correale, Pierpaolo
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 69 - 77
  • [38] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [39] Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review
    Morimoto, Takashi
    Fujito, Kaori
    Yamasaki, Bumpei
    Goto, Rei
    CLINICAL THERAPEUTICS, 2023, 45 (01) : 41 - 54
  • [40] Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer
    Marinho, J.
    Leao, I.
    Neto, E.
    Guedes, H.
    Costa, T.
    Capela, A.
    Moreira Pinto, A.
    Custodio, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S168 - S169
12345